Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 9/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | HPGD | P15428 | 3/20 | 0.63 |
| ▸ | RAB9A | P51151 | 3/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | GLA | P06280 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | ATM | Q13315 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.57 |
| ▸ | MMP13 | P45452 | 3/20 | 0.56 |
| ▸ | MMP2 | P08253 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30190576 | 1.00 | ALOX15 (1.00) | ALOX15KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL3498936 | 0.89 | ALOX15 (0.80) | ALOX15KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL42366 | 0.88 | ALOX15 (0.79) | ALOX15KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL31264281 | 0.88 | ALOX15 (0.79) | ALOX15KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL5623372 | 0.85 | KDM4E (0.78) | ALOX15KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL17368519 | 0.84 | ALOX15 (0.72) | ALOX15KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL71101 | 0.84 | ALOX15 (0.72) | ALOX15KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL4907791 | 0.84 | ALOX15 (0.72) | ALOX15KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL5917452 | 0.83 | ALOX15 (0.71) | ALOX15MAPTPDGFRBFLT3ALPL | |
| SCHEMBL5917481 | 0.82 | ALOX15 (0.70) | ALOX15KDM4EALDH1A1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113831275-A | Indole-substituted 6-phenylindenoindole derivative and preparation method and application thereof | 上海兆维科技发展有限公司 | 2021-12-24 | — | — | CN | claimed |
| US-12570632-B2 | Indole derivatives and uses thereof for treating a cancer | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2026-03-10 | — | — | US | disclosed |
| US-12441724-B2 | Inhibitors of plasma kallikrein and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-10-14 | — | — | US | disclosed |
| CN-115720578-B | And tricyclic derivatives, preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-119350315-A | 2- (1H-indole-2-yl) -1,3, 4-oxadiazole derivatives, and preparation method and application thereof | 南开大学 | 2025-01-24 | — | — | CN | disclosed |
| EP-4175718-B1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | UNIV CLAUDE BERNARD LYON (FR) | 2024-10-02 | — | — | EP | disclosed |
| CN-115843271-B | Indole derivatives and their use for the treatment of cancer | 克洛德贝纳尔-里昂第一大学 | 2024-08-13 | — | — | CN | disclosed |
| CN-111757884-B | Substituted macrocyclic indole derivatives | 拜耳股份公司 | 2023-12-19 | — | — | CN | disclosed |
| US-11760752-B2 | Carboxylic acid, acyl sulfonamide and acyl sulfamide-derivatized bicyclic aza-heteroaromatics as selective Mcl-1 inhibitors and as dual Mcl-1/Bcl-2 inhibitors | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760752-B2 | Carboxylic acid, acyl sulfonamide and acyl sulfamide-derivatized bicyclic aza-heteroaromatics as selective Mcl-1 inhibitors and as dual Mcl-1/Bcl-2 inhibitors | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-09-19 | — | — | US | disclosed |
| US-6441004-B1 | INDOLE DERIVATIVES AS ANTIINFLAMMATORY AGENTS | ZENECA LIMITED (GB) | 2002-08-27 | — | — | US | disclosed |
| US-6395729-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | SANOFI-SYNTHELABO (FR) | 2002-05-28 | — | — | US | disclosed |
| US-20020035110-A1 | Anti-obesity 1,2,3,4,10,10-a-hexahydropy razino [1,2-a] indoles | VERNALIS RESEARCH LIMITED, A BRITISH COMPANY (GB) | 2002-03-21 | — | — | US | disclosed |
| WO-2002010169-A1 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-07 | — | — | WO | disclosed |
| EP-1147110-A1 | PYRAZINO(AZA)INDOLE DERIVATIVES | VERNALIS RESEARCH LIMITED (GB) | 2001-10-24 | — | — | EP | disclosed |
| US-6262045-B1 | TREATMENT OF ANXIETY; SLEEP DISORDER; EPILEPSY; SPASTICITY; MUSCLE CONTRACTURE OR AN EXTRAPYRAMIDAL SYNDROM; INDUCING OR MAINTAINING ANAESTHESIA | SANOFI-SYNTHELABO (FR) | 2001-07-17 | — | — | US | disclosed |
| WO-2000044753-A1 | PIRAZINO(AZA)INDOLE DERIVATIVES | VERNALIS RESEARCH LIMITED (GB) | 2000-08-03 | — | — | WO | disclosed |
| EP-1003504-A2 | INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS | AstraZeneca UK Limited (GB) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999007351-A2 | INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS | ZENECA LIMITED (GB) | 1999-02-18 | — | — | WO | disclosed |
| US-4137313-A | ANTICOAGULANTS, ANTIPHLOGISTIC AGENTS | BOEHRINGER INGELHEIM GMBH (DE) | 1979-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570632-B2 | Indole derivatives and uses thereof for treating a cancer | CKS2, CSNK2A3, CSNK1A1L | ALOX15 3186/4885KDM4E 2594/4885ALDH1A1 1571/4885 |
| US-12441724-B2 | Inhibitors of plasma kallikrein and uses thereof | KLKB1, KLK1, KLK5 | ALOX15 1564/4885KDM4E 738/4885ALDH1A1 3157/4885 |
| US-11760752-B2 | Carboxylic acid, acyl sulfonamide and acyl sulfamide-derivatized bicyclic aza-heteroaromatics as selective Mcl-1 inhibitors and as dual Mcl-1/Bcl-2 inhibitors | MCL1, BCLAF1, BCL2A1 | ALOX15 1733/4885KDM4E 1872/4885ALDH1A1 353/4885 |
| US-20020035110-A1 | Anti-obesity 1,2,3,4,10,10-a-hexahydropy razino [1,2-a] indoles | GPR119, HTR1D, HTR1A | ALOX15 261/4885KDM4E 657/4885ALDH1A1 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.